P.1.i.024 Arnold-Chiari type I malformation with psychiatric symptoms: a case report

Orhan, Fatma Özlem; Yüksel, Zehre; Altunören, Orçun; Altun, İnsaf; Berk, Şule Şirin; Akman, O.; Karaaslan, Mehmet

doi:10.1016/s0924-977x(09)70530-9

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, BDNF was measured 1 week after treatment completion. Our non-significant findings conflict with those of Piccini et al (2009) who found that serum BDNF levels are increased 1 week after the completion of ECT. In contrast, Bocchio-Chiavetto et al (2006) found that BDNF levels were not altered 1 week after ECT, however BDNF levels increased 1 month after treatment compared to pre-treatment levels.…”

Section: Discussioncontrasting

confidence: 99%

“…However, the timepoint at which post-treatment BDNF levels are measured is not consistent across previous studies. Serum BDNF levels have been measured during treatment (Marano et al, 2007), 5 weeks after the start of ECT (Okamoto et al, 2008), as well as 1 week (Piccini et al, 2009), 2 weeks (Hu et al, 2010), or 1 month (Bocchio-Chiavetto et al, 2006) after treatment completion. Therefore, while ECT may increase BDNF levels, it remains unclear as to when this increase occurs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation on Serum Brain-Derived Neurotrophic Factor Levels in Patients with Depression

Gedge¹,

Beaudoin²,

Lazowski³

et al. 2012

Front. Psychiatry

View full text Add to dashboard Cite

Objective: Brain-derived neurotrophic factor (BDNF) levels are decreased in individuals with depression and increase following antidepressant treatment. The objective of this study is to compare pre- and post-treatment serum BDNF levels in patients with drug-resistant major depressive disorder (MDD) who received either electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS). It is hypothesized that non-pharmacological treatments also increase serum BDNF levels. Methods: This was a prospective, single-blind study comparing pre- and post-treatment serum BDNF levels of 29 patients with drug-resistant MDD who received ECT or rTMS treatment. Serum BDNF levels were measured 1 week prior to and 1 week after treatment using the sandwich ELISA technique. Depression severity was measured 1 week before and 1 week after treatment using the Hamilton Depression Rating Scale. Two-sided normal distribution paired t-test analysis was used to compare pre- and post-treatment BDNF concentration and illness severity. Bivariate correlations using Pearson’s coefficient assessed the relationship between post-treatment BDNF levels and post-treatment depression severity. Results: There was no significant difference in serum BDNF levels before and after ECT, although concentrations tended to increase from a baseline mean of 9.95–12.29 ng/ml after treatment (p = 0.137). Treatment with rTMS did not significantly alter BDNF concentrations (p = 0.282). Depression severity significantly decreased following both ECT (p = 0.003) and rTMS (p < 0.001). Post-treatment BDNF concentration was not significantly correlated with post-treatment depression severity in patients who received either ECT (r = −0.133, p = 0.697) or rTMS (r = 0.374, p = 0.126). It is important to note that these results are based on the small number of patients included in this study. Conclusion: This study suggests that ECT and rTMS may not exert their clinical effects by altering serum BDNF levels in patients with drug-resistant MDD. Serum BDNF concentration may not be a biomarker of ECT or rTMS treatment response.

show abstract

Section: Discussioncontrasting

confidence: 99%